ArriVent BioPharma (AVBP) Securities Investigation Notice

ArriVent BioPharma’s pivotal Phase 3 FURVENT trial of firmonertinib missed its primary endpoint, progression-free survival, sending AVBP shares down approximately 50%–63% on October 6, 2026, to a reported 52-week low near $12.09; another report cited an intraday low of $11.88. The company reported some secondary-endpoint benefits and no new safety signals. Levi & Korsinsky is investigating potential securities-law violations on behalf of investors.

Analysis

The key issue is not the one-day repricing but whether any remaining asset value can support a floor. A pivotal PFS miss raises the burden of proof for firmonertinib: unspecified secondary-endpoint benefits are not a substitute for a prespecified primary endpoint, and their investment value depends on effect size, statistical hierarchy, durability, and whether regulators see a viable path. The commercial opportunity may shift toward established EGFR exon 20 treatment options, including Johnson & Johnson’s amivantamab-based regimen, but the size of any share transfer is unquantifiable from this release.

Near term, this is a binary-data and liquidity story, not a clean valuation short. After a 50%+ gap, residual cash, burn rate, other pipeline assets, and firmonertinib rights determine downside; none is provided. Over 1–3 months, full trial results, management’s regulatory interpretation, and any development reprioritization are the catalysts. Over 6–18 months, a credible confirmatory-development path or partnership could preserve option value; absent that, capital allocation and financing dilution become more important risks. The securities-law investigation is attorney advertising, not evidence of misconduct or a near-term fundamental catalyst. Contrarian point: the fall may be directionally justified yet still overshoot if the market is valuing the company as though it has no cash or other assets. Verify filings before assigning a floor.

Key Decisions for Investors

• Avoid initiating or averaging into AVBP until reviewing the full FURVENT data and latest filings. Specifically verify cash and investments, quarterly burn, debt or other obligations, pipeline beyond firmonertinib, and geographic/licensing rights.
• Do not chase a short solely on the headline gap: residual-asset uncertainty and event-driven volatility create sharp squeeze risk. Reassess after management’s data discussion; a short becomes more defensible only if the remaining asset and cash value do not support the post-gap equity value.
• Watch for the 1–3 month catalysts: complete PFS and secondary-endpoint data, subgroup consistency, regulatory feedback, and any disclosed trial or portfolio reprioritization. A credible regulator-supported path would falsify the most bearish development thesis; weak or non-durable secondary results would reinforce it.
• Treat the litigation notice as non-actionable for trading unless a formal filing or company disclosure adds material facts. It does not establish liability or change the clinical read-through.